MARLBOROUGH, Mass., June 16, 2014 /PRNewswire/ --Lemelson Capital Management, a private investment management firm, today released a 25 page research report on Ligand Pharmaceuticals (NASDAQ: LGND).
The full research report on Ligand can be found here.
Disclosure: Lemelson Capital is currently short shares of LGND for its clients.
About Lemelson Capital Management
Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds. For more information, see: http://www.lemelsoncapital.com
For further information, please contact:
+ Emmanuel Lemelson
Chief Investment Officer
Lemelson Capital Management, LLC
Telephone: 508-630-2281
SOURCE Lemelson Capital Management, LLC
